Neuromodulation in Management of Overactive Bladder by Hitoshi Oh-Oka
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
2 
Neuromodulation in Management of  
Overactive Bladder  
Hitoshi Oh-Oka 
Department of Urology, Kobe Medical Center, Kobe 
Japan 
1. Introduction 
Symptoms of urgency and frequency, with or without incontinence, are collectively referred 
to as overactive bladder (OAB), that is particularly bothersome and worsens quality of life 
(QOL) (Cardozo et al., 2005). Patients’ QOL is substantially impacted by OAB as social, 
psychological, occupational, domestic, physical, and sexual functioning are all affected 
(Abrams et al., 2000). Pharmacotherapy (anticholinergics) is the main treatment options in 
OAB. However, uncertainty still exists as to whether the effects of anticholinergics are 
worthwhile and which ones and which is the best route of administration. 
Neuromodulation is one of the non-drug alternatives of OAB managements like bladder 
training, pelvic floor muscle training (PFMT), and a combination of bladder training with 
biofeedback (Bergmans et al., 2005). Neuromodulation involves the use of either implanted 
or external electrodes to stimulate reflex inhibition of pelvic efferents or activation of 
hypogastric efferents to down regulate detrusor muscle activity (Alhasso et al., 2006). But, 
neuromodulation has not been widely accepted as first-line therapy because of few 
physiological and evidence based data. Patients with OAB are commonly treated using 
anticholinergics despite many adverse events (mainly dry mouth and constipation) (Abrams 
et al., 2006), possible poor medication adherence, and insufficient treatment satisfaction. 
I review the current reports regarding neuromodulation and evaluate its efficacy and 
management mainly focused on interferential therapy (IF) in the treatment of OAB with and 
without urinary incontinence (wet & dry OAB). 
2. Interferential therapy 
2.1 History 
IF utilizing effects of low frequency electrical stimulation was first conducted on the lower 
urinary tract in the treatment of urinary incontinence or urinary frequency, resulted in a 
clinical improvement (McQuire, 1975). The utility of this therapy for conditions such as 
urinary frequency, urge incontinence (UUI) and stress incontinence (SUI) was subsequently 
reported by several researchers (Dougall, 1985; Laycock and Green, 1988; Switzer and 
Hendriks, 1988). Yasuda reported the efficacy of IF over sham stimulation in double-blind 
cross over trial in Japanese patients regarding frequency, urgency and urinary incontinence 
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(UI) and revealed clinical efficacy of IF for neurogenic detrusor overactivity, idiopathic OAB 
and psychogenic pollakisuria (Yasuda et al., 1994). Suzuki reported the long term efficacy of 
IF with a mean follow-up of 6.7 months in 16 patients, with improvement rate 71.4% (Suzuki 
et al., 1994). Oh-oka reported clinical safety and efficacy of IF in the elderly wet OAB 
patients followed by treatment failure of anticholinergics (Oh-oka, 2008).  
2.2 Basic principles/mechanisms 
IF assumes the interference of two medium frequency currents producing a low frequency 
effect equal to the difference between the two currents around 4000Hz, that are applied to 
the body from different directions using four surface electrodes placed in the lower 
abdomen and lower buttocks, after that an interferential wave can be generated by the 
crossing of these two currents in the pelvic organs (bladder and pelvic floor). The 
mechanism for the treatment of OAB, including UUI, has been reported to include, 1) 
inhibition of efferent activities of the pelvic nerve through the somatosensory nerve 
stimulation in the pudendal region (action on the micturition center in the brainstem and the 
spinal cord) (Kimura et al.,1994; Sato et al., 1992), 2) increasing the pelvic blood flow 
(Nikolova, 1984), and 3) improving the urine storage function of the bladder and urinary 
tract through the sympathetic nerve (hypogastric nerve) (Kaeckenbeech, 1983). Of these, 
mechanism 1) appears to be most essential. 
2.3 Clinical efficacy 
A 20-minute treatment session was conducted twice a week for the first 3 weeks, and once 
every two weeks thereafter in Japan. Ease of usage and external application without giving 
harm to the superficial tissues are the main advantages of IF. The current and the intensity is 
well tolerated by the patients (Laycock and Green, 1988). Appropriate treatment frequencies 
of IF in patients with wet & dry OAB are generally 5 to 20Hz for reflex detrusor inhibition, 
but low frequencies such as 5 Hz may cause irritation (Yamanishi & Yasuda, 1988; Goode 
et.al., 2003), which can be resolved by reducing electric current. In patients with stress 
incontinence (SUI), frequencies ranging 20 to 50 Hz have been reported to be effective for 
urethra and pelvic floor (Yamanishi & Yasuda, 1988; Aukee et al., 2002). The frequency and 
period of stimulation vary according to investigators, from twice daily to once weekly, for 
15 to 30 min. each, and from a month to 6 weeks, or 3-5 months (Yamanishi et al., 1997; Sand 
et al., 1995; Yamanishi et al., 2008). The optimal number of sessions required is still 
unknown, at least 10 treatments are recommended before the evaluation of clinical efficacy 
(Sand et al., 1995), and a session of 4-6 weeks is conventionally employed (Yamanishi et al., 
1997; Li et al., 1992). For about the intensity of stimulation, the maximal tolerable intensity is 
usually employed (Yamanishi et al., 1997; Sand et al., 1995; Plevnik and Janez, 1979). 
Yasuda et al. reported clinical efficacy of IF for patients with neurogenic detrusor 
overactivity (DO), idiopathic OAB and psychogenic pollakisuria. Subjective variables 
(patients’ impression>good, improvement in urgency) and objective variables 
(improvement in pollakisuria, incontinence, 1-hr. pad test, overall improvement) had all 
improved significantly over sham stimulation. Furthermore, improvement was statistically 
significant in patients with neurogenic bladder (n=32, p<0.01) and urodynamic SUI (n=17, 
p<0.01) (Yasuda et al., 1994). Suzuki et al. reported clinical efficacy of IF with mean follow-
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up of 6.7±3.9 months in 16 patients with neurogenic DO, idiopathic OAB and psychogenic 
pollakisuria. Clinical efficacy of subjective variables (categorical scale of urinary 
frequency, urgency, patients’ impression>good and overall improvement) were 46.7%, 
53.3%, 81.3% and 71.4%, respectively. As for objective variables (urinary frequency, 
categorical scale of urinary incontinence (UI) frequency, incontinence volume) were 
46.2%, 70.0% and 70.0%, respectively (Suzuki et al, 1994). Oh-oka reported the clinical 
efficacy of IF in 80 elderly non-neurogenic (idiopathic) OAB patients (69-78, median age 
72.0) with UUI prospectively, for whom anticholinergics (propiverine hydrochloride) 
were not effective, who were provided with IF alone for three months (Table 1). In this 
paper he commented not only QOL score, but changes in lifestyle and plasma osmotic 
pressure (OP), brain natriuretic peptide (BNP). The average hours spent outdoors in one 
day, the one-day average radius of action increased, and the ADL scale score decreased; 
all these improvements were significant. Interviews from patients showed that all patients 
experienced increases in their amount of outdoor activities, time spent for shopping and 
hobbies, and time spent with their friends and close relatives. Also, OP increased 
significantly while BNP decreased significantly. These data indicate even in the absence of 
clinically evident cardiac disorders, OP and BNP levels can be high and that such levels 
are lowered in a relatively short period of time. IF can improve clinical symptoms of ‘wet 
OAB’ with relatively rapidly and thereby can improve ADL levels, implying a reduced 
load on left ventricular function. These features suggest that IF is a favorable treatment for 
the elderly, and for more than 1 year continuation of all 80 patients at their own request 
revealed satisfactorily compliance of IF (Oh-oka, 2008).  
baseline (pre IF) post IF p value
frequency of IF treatment required to show optimal effects eight treatments (median)
average weekly frequency of incontinence (times/week) 13.3 ± 5.2 3.6 ± 3.5 < 0.0001
60-min. pad test (gr.) 17.5 ± 2.1 3.1 ± 2.1 < 0.0001
daytime voiding episodes (times) 8.3 ± 2.4 7.0 ± 1.8 < 0.0001
nighttime voiding episodes (times) 1.8 ± 1.0 1.4 ± 1.0 0.0004
daytime voided volume (mL) 1199 ± 230 1220 ± 320 NS
nighttime voided volume  (mL) 514 ± 185 464 ± 157 NS
IPSS 12.1 ± 5.3 6.3 ± 3.3 < 0.0001
QOL index 5.2 ± 0.8 2.4 ± 1.1 < 0.0001
Uroflowmetry variable
voided vol. (mL) 170.2 ± 84.8 254.2 ± 60.6 < 0.0001
maximum flow rate (mL/sec.) 18.1 ± 6.8 25.7 ± 6.6 < 0.0001
average flow rate (mL/sec.) 8.9 ± 4.1 12.1±3.5 < 0.0001
postvoid residual urine volume (mL) 17.5 ± 24.0 14.5 ± 23.1 NS
specific gravity of urine 1.019 ± 0.007 1.016 ± 0.006 NS
The average hours spent outdoors in one day (hours) 1.5 ± 1.3 3.0 ± 1.4 < 0.0001
the one-day average radius of action (meters) 400 ± 300 1200 ± 500 < 0.0001
ADL scale score 8.0 ± 1.2 3.4 ± 1.5 < 0.0001
Plasma osmotic pressure (mOsm/L) 295.1 ± 7.8 297.8 ± 3.6 < 0.0001
brain natriuretic peptide (pg/mL) 41.3 ± 38.7 19.2 ± 11.1 < 0.0001
IF; interferential therapy, IPSS; International Prostate Symptom Score, QOL; Quality of Life, ADL; Activities of Daily Living, NS; not significant
This data was modified from prior published work (Oh-oka, 2008, 2010)
 
Table 1. Amticholinergic resistant elderly wet OAB patients after 12 weeks of IF 
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Before and after IF, the follows were examined. 1) frequency of IF treatment required to show 
optimal effects, 2) average weekly episodes of incontinence, 3) 60-min. pad test, 4) episodes 
and voided volume in the daytime and nighttime, 5) fluid intake volume, 6) International 
Prostate Symptom Score (IPSS), QOL index, 7) Uroflowmetry, 8) postvoid residual urine 
volume (PVR), 9) specific gravity of urine, 10) average hours spent outdoors, 11) average 
radius of action and activities of daily life score, 12) standing blood pressure (BP) and heart 
rate, 13) clinical laboratory findings, 14) adverse events, 15) plasma osmotic pressure (OP), and 
16) Brain natriuretic peptide. And the patients showed improvements for eight treatments 
(median). Improvement was observed in the followings; 2), 3), 4) voiding frequency, 6), 7) 
voided volume, maximal and average flow rate, 10), 11), 12) BP, 15) OP, and 16). 
Demirtürk F et al. reported comparison to the effects of interferential current (0-100 Hz, 15 
min., 3 times/week) and biofeedback applications (Kegel exercise, 15 min., 3 times/day) on 
incontinence severity in patients with 40 USI women and resulted both treatment modalities 
seemed to have similar effects on pad test (95% CI: -1.48 - 4.59), pelvic muscle strength (95% 
CI: -9.29 -1.78) and quality of life (95% CI: -11.91 - 5.31) outcomes (Demirtürk et al., 2008). 
2.4 Challenges/future prospects 
Currently, only interferential therapy using the Uromaster® is approved for use in the 
treatment of OAB and UI in Japan. IF reports regarding clinical efficacy or basic research in 
OAB are very few, and good, randomized, placebo controlled studies have rarely 
performed. Applying uniformly set treatment modalities (treatment parameters and 
schedules), long term data on the clinical outcome, also concerning the patients’ 
characteristics (definition and duration of symptoms, previous treatment) is very important 
and urgently necessary (van Balken et al., 2004). Also combination effect with PFMT or 
anticholinergics should be further analyzed strictly to manage OAB for the future. On the 
other hand, advantages of IF include; the absence of complications such as increased 
episodes and (nighttime) voided volume resulting from more water intake to counter dry 
mouth, which is an bothersome adverse event observed with the use of anticholinergics 
including propiverine hydrochloride; and satisfactory compliance that can be achieved in 
patients who are not indicated for oral treatment or are incapable of oral ingestion. IF is 
suitable for short-term electrical stimulation for home use (portable IF devices are available, 
that are unauthorized for medical equipment in Japan). 
3. Pelvic floor electrical stimulation 
3.1 History 
Caldwell reported the successful implantation of an anal sphincter stimulator for fecal 
incontinence, which proved to be effective for urinary incontinence (Caldwell, 1963). Anal 
plug electrodes were subsequently modified. Later Fall et al. provided reports regarding 
transvaginal electrical stimulation with urinary incontinence and interstitial cystitis (Fall et 
al., 1977, 1980, 1984).  
3.2 Basic principles/mechanisms  
Vaginal, anal, and surface electrodes are used for pelvic floor electrical stimulation. Vaginal 
electrode is popular for women, and anal electrode is usually used for men. The mechanism 
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of these techniques was detrusor relaxation induced by afferent pathways including 
activation of hypogastric inhibitory neurons, inhibition of pelvic excitatory neurons with 
pudendal nerves (Lindström, 1983).  
3.3 Clinical efficacy 
Because of poor tolerability due to pain or discomfort of intravaginal and anal plug 
electrodes, surface electrical stimulation of dorsal nerve of penis or clitoris (transcutaneous 
electrical stimulation [TENS]) has been often adopted as low invasive modality for DO. The 
alternative TENS treatments was thought S2 or S3 dermatome, which might improve clinical 
outcome (Walsh et al, 1999). Comparison of neuromodulation to sham TENS, no TENS, other 
TENS including suprapubic or tibial nerve TENS, and medical treatment including 
anticholinergics is important. These studies resulted in a positive effect on detrusor instability 
(DI), an improvement in the first desire to void and increased bladder capacity on 
urodynamics. Some DI patients become stable, while in others the volume at first contraction 
improved significantly. For permanently decreasing incontinence TENS alone might be 
insufficient. Superiority of clinical efficacy between oxybutynin and electrical stimulation 
(intravaginal or TENS) in controversial (Soomro et al, 2001; Wang et al, 2006), but the 
prevalence of electrical stimulation devices might not enough (Walsh et al, 1999). Arruda RM 
et al. reported the effectiveness of oxybutynin, functional electrostimulation (transvaginal) and 
pelvic floor training for treatment of 64 women with DO after completion of 12 weeks of 
treatment and resulted all three treatments were equally effective for improvement rate of 
subjective symptoms, urgency and urodynamic cure (Arruda et al., 2008). 
3.4 Challenges/future prospects 
Intravaginal and anal plug are sometimes intolerable for many patients due to discomfort, 
mucosal injury (Yamanishi et al., 1997; Yamanishi & Yasuda, 1998) and high intensity 
stimulation for acceptable outcome, surface electrodes like TENS have been employed as 
less invasive treatment for OAB.  
4. Electrical tibial nerve stimulation of the lower limb 
4.1 History 
During experimental studies in nonhuman primates with spinal cord injury to improve 
bipolar anal sphincter Stimulation, McGuire et al. found that detrusor activity inhibition was 
equally achieved by applying a positive current to the anal sphincter with a negative 
electrode placed over the posterior tibial nerve (McGuire et al., 1983). Similar results were 
obtained by applying current on the common peroneal or posterior tibial nerve and a 
ground electrode placed over the same nerves contralaterally. The idea of stimulating tibial 
nerve was based on the traditional Chinese practice of using acupuncture points to inhibit 
bladder activity (McGuire et al., 1983). Transcutaneous posterior tibial nerve stimulation 
was then evaluated in clinical trials with variable results. 
4.2 Basic principles/mechanisms  
Percutaneous tibial nerve stimulation (PTNS) delivers neuromodulation to the pelvic floor 
through the S2-4 junction of the sacral nerve plexus via the less invasive route of the 
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posterior tibial nerve. Using the fine needle electrode insertion above the ankle, the tibial 
nerve is accessed. This area has projections to the sacral nerve plexus, creating a feedback-
loop that modulates bladder innervation (Kohli & Rosenblatt, 2002).  
4.3 Clinical efficacy 
Govier et al. reported a safety and efficacy of PTNS for refractive OAB and/or pelvic floor 
dysfunction (Govier et al., 2001). Klingler et al. demonstrated reduction in pain and 
urodynamic improvement of DI, total bladder capacity, first bladder sensation, bladder 
volume at normal desire to void, and urinary frequency (Klingler et al., 2000). Peters et al. 
demonstrated the objective effectiveness of PTNS in OAB symptoms compared to extended-
release tolterodine (Peters et al., 2009). PTNS is also effective for disease related DO (DO in 
multiple sclerosis, Parkinson’s disease).  
4.4 Challenges/future prospects 
PTNS is less invasive, easily applicable, and well tolerated in all lower urinary tract 
conditions. Poor improvements in urodynamic studies, like other neuromodulation 
therapies, might be the main disadvantage, and it seems doubtful regarding the stable 
efficacy of chronic (over 10 to 12 weeks) treatment (van Balken et al., 2004). As in sacral root 
neuromodulation, PTNS seems less effective for improving chronic pelvic pain (van Balken 
et al., 2003). 
5. Sacral nerve stimulation 
5.1 History 
In 1981 a group at the urological department at the University of California-San Francisco 
started a clinical program to evaluate the efficacy of sacral root electrode implantation in 
humans, leading to the humans (Tanagho & Schmidt, 1988; Schmidt, 1986). Since then, many 
reports regarding sacral nerve stimulation have been published as the technique has gained 
popularity.  
5.2 Basic principles/mechanisms  
SNS involves continuous electrical stimulation of the sacral nerves to inhibit or activate the 
neural reflexes that influence the bladder, urethral sphincter, and pelvic floor (Shaker & 
Hassouna, 1988; van Kerrebroek et al., 2007; Oerlemans & van Kerrebroek, 2008). Thus, SNS 
has been indicated for various types of lower urinary tract dysfunction refractory to 
conservative treatment, such as wet & dry OAB, pelvic pain syndrome and urinary retention 
(UR) (Oerlemans & van Kerrebroek, 2008; Shaker & Hassouna, 1998). In patients with OAB, 
SNS would restore the balance between inhibitory and excitatory control systems at various 
sites in the peripheral and central nervous system. This would involve activation of 
somatosensory bladder afferents projecting into the pontine micturition center, and/or 
activation of the hypogastoric sympathetic nerves (van der Pal et al., 2006). Also, Blok et al. 
reported changes in regional cerebral blood flow, using positron emission tomography, 
during chronic and acute sacral neuromodulation. They suggest chronic SNS influences, 
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presumably via the spinal cord, brain areas previously implicated in detrusor hyperactivity, 
awareness of bladder filling, the urge to void and the timing of micturition (Blok et al., 
2006). Furthermore, SNS affects areas involved in alertness and awareness.  
5.3 Clinical efficacy 
A percutaneous nerve stimulation (PNE) of the S3 roots for 1-4 weeks is used to select 
responders of neuromodulation, and patients who are eligible for permanent implantation 
shift to a chronic stimulation system (Chartier-Kastler, 2008). To prolong test period safely 
(reduce the risk of infection and surgical invasiveness) and to avoid false-negative results 
due to lead migration, PNE with the permanent tined lead under local anesthesia is also 
available (Spinelli et al., 2005). Schmidt et al. reported success rate of 63% (test stimulation) 
in 155 patients with refractory UUI. Sustained clinical benefit was reported at 18 months 
after implantation (Schmidt et al., 1999). Jonas et al. reported efficacy with refractory 
idiopathic UR who are refractory to other treatments. Success rate of SNS was 83%, 
including 69% who stopped using catheters at 6 months after implantation (Jonas et al., 
2001). Shaker and Hassouna reported a marked reduction in leakage episodes from 6.49 to 
1.98 times per 24 hours, and eight of 18 patients became completely dry after an average 
follow-up was 18.8 months (Shaker & Hassouna, 1988). Sutherland et al. reported their one 
institution's 11-year experience with SNS in 104 patients including dry, wet OAB and mixed 
incontinence. With a mean follow up of 22 months (range 3-162 months), sustained 
subjective improvement was >50%, >80%, and >90% in 69%, 50%, and 35% of patients, 
respectively. By QOL survey, 60.5% of patients were satisfied with current urinary 
symptoms (Sutherland et al., 2007). 
To shorten operation time and decrease pain complaints at the stimulator site buttock 
placement was advocated. The unilateral SNS might result in malposition of the electrode or 
local fibrosis. Hohenfellner et al. recommended clinical efficacy of bilateral SNS than 
unilateral SNS (Hohenfellner et al., 1998). Aboseif et al. reported the efficacy and QOL 
improvement of SNS in patients with idiopathic, chronic, non-obstructive functional UR. 
Permanent implants were performed 20 patients who revealed more than 50% improvement 
in symptoms during the PNE test. Eighteen patients were subsequently able to void and no 
longer required intermittent catheterization. Average voided volumes increased from 48 to 
198 ml and PVR reduced from 315 to 60 ml. Eighteen patients reported more than a 50% 
improvement in QOL (Aboseif et al., 2002). New approaches of bilateral caudal 
neuromodulation might yield excellent outcome in patients with urinary retention 
refractory to traditional, unilateral S3 stimulation (Maher et al., 2007). 
5.4 Challenges/future prospects 
Sacral nerve stimulation (SNS) is an established treatment for OAB. Adverse events related 
to SNS can be the physical presence of the device or adverse stimulation. Van Kerrebroek et 
al. reported adverse events seemed to occur in 102 patients (67%) at 5-year follow-up, and 
the most frequent events being new pain or undesirable change of stimulation (27%) (van 
Kerrebroek et al., 2007). Adverse stimulation does not necessarily require surgical 
intervention. It is often resolved by changing stimulation factors (pulse width, amplitude, 
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mode of polarity etc.). Pain in implant site or scar pain could be adequately treated by 
antimicrobial agents, while device pain might require relocation of the device components. 
Hijaz et al. reported 10.5% of patients were explanted due to loss of efficacy or infection. In 
16.1% of the patients, adverse events (implant site discomfort in 2.5%, lead migration in 
0.6% and infection in 2.5%) or decreased efficacy (10.5%) could be managed successfully 
(Hijaz et al., 2006). 
6. Magnetic stimulation 
6.1 History 
Magnetic stimulation has been used for experimental and clinical testing on the central and 
peripheral nervous systems (Barker et al., 1987). Compared to electrical stimulation, 
magnetic stimulation is useful to stimulate deep proximal nerves with little pain due to 
magnetic penetration of all body tissues without alteration. Also patients are not necessary 
to take off clothes during treatment because the magnetic field passes through clothes.  
6.2 Basic principles/mechanisms  
A varying magnetic field will induce an electrical field in any specified loop in its vicinity. 
The roots of sacral nerves S2-S4 provide the primary autonomic and somatic innervations of 
the urinary tract, including pelvic floor, urethra, bladder and other pelvic organs, and 
stimulation of these roots is an efficient way to modulate the pelvic floor and control 
functions of pelvic organs (Shafik, 2000). Magnetic stimulation can be applied both at the 
sacral root (Sheriff et al., 1996; Fujishiro et al., 2002) and the peri-anal region (Yamanishi et 
al., 2000; Galloway et al., 1999). However, the commercially available stimulator is usually a 
chair type and stimulates the peri-anal region including pelvic floor muscles because of 
difficulty to fix the coil to the sacral root for a long time.  
6.3 Clinical efficacy 
Reductions in the frequency of leakage and urodynamic improvement of maximum bladder 
capacity in UUI and increase in maximum urethral closing pressure in USI by continuous 
magnetic stimulation have been reported (Yamanishi et al, 2000a, 2000b). Unsal et al. 
reported the clinical efficacy of extracorporeal magnetic stimulation for the treatment of SUI 
and UUI in women (Unsal et al., 2003). Fujishiro et al. reported an investigational study and 
placebo controlled trial to evaluate the potential efficacy of magnetic stimulation of the 
sacral roots for the treatment of stress incontinence. They concluded significant efficacy for 
the treatment of UUI and SUI (Fujishiro et al., 2000 & 2002). Yamanishi et al reported a 
randomized comparative study investigating the urodynamic effects of functional magnetic 
stimulation (FMS) and functional electrical stimulation (FES) on the inhibition of detrusor 
overactivity, and concluded that both treatments were effective in the increase of first desire 
to void and maximum cystometric capacity. But the increase in the maximum cystometric 
capacity was significantly greater in FMS than FES group, also the inhibition of detrusor 
overactivity appeared greater in FMS than FES group (Yamanishi et al, 2000). Suzuki et al. 
reported the effect of functional continuous magnetic stimulation (FCMS) on urgency 
incontinence using a randomized, sham-controlled, crossover evaluation in 39 UUI patients. 
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They concluded magnetic stimulation was effective on UUI in comparison to sham 
stimulation (Suzuki et al, 2007). However, Culligan et al. reported no differences in pelvic 
muscle strength between patients receiving active or sham extracorporeal magnetic 
innervation treatments (ExMI) in the early postpartum period (Culligan et al., 2005). 
Voorham-van der Zalm et al. reported the clinical results of extracorporeal magnetic 
innervation therapy (ExMI) of the pelvic floor muscles with functional changes in the pelvic 
floor musculature, urodynamics and quality of life, and concluded ExMI did not change 
pelvic floor function (Voorham-van der Zalm et al., 2006). There are varying outcomes of 
several studies on ExMI stress the need for critical studies on the effect and the mode of 
action of electrostimulation and magnetic stimulation. 
6.4 Challenges/future prospects 
This type of stimulation cannot be applied for prolonged periods and unsuitable for long-
term treatment, although it may be helpful for preliminary assessment of candidates for 
chronic sacral root neuromodulation. It is unclear if the exact mechanism of action is 
magnetic, nerve root, peripheral nerve, or intramural nerve stimulation. No prospective 
randomized studies to date have been performed to demonstrate this therapy’s use in larger 
groups regarding UUI or USI. 
7. Conclusions 
Although the use of electrical stimulation and neuromodulation to treat patients with 
OAB has been widely investigated, in many reports important information is not enough 
and good randomized, placebo controlled studies are rare. The advent of various 
techniques of neuromodulation causes paradigm shift of treatment strategies of patients 
with OAB and other lower urinary tract dysfunction. We should compare various 
techniques and evaluate placebo effects overcoming unsolved aspects of the current 
treatment including neuromodulation. And our better approaches based on further 
understanding of voiding function and action mechanism of neuromodulatory techniques 
might lead more various types of patients with urinary tract dysfunction to more 
satisfactorily clinical outcomes. In consideration of these problems, I personally expect 
potential clinical efficacy of IF as short-term electrical stimulation, that has few adverse 
event, and improving not only QOL but ADL. 
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